Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity - Cao, Dai; Zhu, Guo-Yuan; Lu, Yan; Yang, Aiping; Chen, Die; Huang, Hui-Jie; Peng, Shu-Xian; Chen, Li-Wen; Li, Ying-Wei (Biomedicine & pharmacotherapy, 2020)
Keywords: Adaptor Proteins, Signal Transducing - genetics; Adaptor Proteins, Signal Transducing - metabolism; Animals; Antineoplastic Agents - pharmacology; Cell Line, Tumor; Cell Movement - drug effects; Epithelial to mesenchymal transition; Epithelial-Mesenchymal Transition - drug effects; Female; Gene Expression Regulation, Neoplastic; Humans; Luteolin; Luteolin - pharmacology; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Proteolysis; Signal Transduction; Trans-Activators - genetics; Trans-Activators - metabolism; Transcription Factors - genetics; Transcription Factors - metabolism; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - metabolism; Triple Negative Breast Neoplasms - pathology; Triple-negative breast cancer; Tumor Burden - drug effects; YAP/TAZ activity; PR; SRB; DMSO; IHC; HTS; YAP; HIF1/2; CYR61; CTGF; Triple-negative breast cancer; DMEM; FBS; IC50; WWTR1/TAZ; TGF-β; Luteolin; TNBC; NF- κ B; CSCs; TEADs; PBS; Epithelial to mesenchymal transition; DAB; EGF; STAT3; DAPI; ER; EMT; PVDF; TEAD; YAP/TAZ activity; Her2